Skin Cancer

  • Tania Kaprealian
  • James Rembert
  • Lawrence W. Margolis
  • Sue S. Yom


Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of skin are the most common malignancies in the US. Greater than one million unreported cases of BCC and SCC occur annually. Main histologic types: BCC (65%), SCC (35%), adnexal (5%), melanoma (1.5%). More common in men (4:1). Median age: 68 (SCC and BCC). Most common predisposing factor: UV exposure. Other predisposing factors: chronic irritation, trauma, occupational exposure, genetic disorders (phenylketonuria, basal cell nevus syndrome [Gorlin’s], xeroderma pigmentosum, giant congenital nevi), immunosuppression (drug-induced, leukemia/lymphoma, HIV). Common routes of spread: lateral and deep along path of least resistance, perineural invasion (60–70% are asymptomatic), and regional LN. Basal cell carcinoma.


Squamous Cell Carcinoma Basal Cell Carcinoma MERKEL Cell Carcinoma Regional Lymph Node Metastasis Verrucous Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



  1. Ang KK, Byers RM, Peters LJ. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Arch Otolaryngol Head Neck Surg. 1990;116(2):169-172.PubMedCrossRefGoogle Scholar
  2. Ang KK, Peters LJ, Weber RS. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys. 1994; 30(4):795-798.PubMedCrossRefGoogle Scholar
  3. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26:5748-5754.PubMedCrossRefGoogle Scholar
  4. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma –Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol. 2006;81:136-42.PubMedCrossRefGoogle Scholar
  5. Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66(4):1051-1055.PubMedCrossRefGoogle Scholar
  6. Overgaard J, Gonzalez D, Hulshof MC. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995;345(8949): 540-543.PubMedCrossRefGoogle Scholar

Further Reading

  1. Ang KK, Weber RS. Cutaneous Carcinoma. In: Gunderson L, Tepper J, editors. Clinical Radiation Oncology, 2nd ed. Philadelphia: Churchill Livingstone; 2007. pp. 853-864.Google Scholar
  2. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0). Ann Surg Oncol. 2000;7:87-97Google Scholar
  3. Ballo MT, Ang KK. Malignant Melanoma. In: Gunderson L, Tepper J, editors. Clinical Radiation Oncology, 2nd ed. Philadelphia: Churchill Livingstone; 2007. pp. 865-877.Google Scholar
  4. Ballo MT, Zagars GK, Gershenwald JE, et al. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004;11:1079-1084.Google Scholar
  5. Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2003;100:383-389.Google Scholar
  6. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009; 27:1075-1081.Google Scholar
  7. Dana-Farber Cancer Institute. Merkel Cell Carcinoma: Information for Patients and Their Physicians. Available at: Accessed on January 12, 2005.
  8. Doubrovsky A, de Wilt JH, Scolyer RA, et al. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol. 2004;11:829-836.Google Scholar
  9. Greene FL. American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag; 2002.Google Scholar
  10. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.Google Scholar
  11. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.Google Scholar
  12. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14:7-17.Google Scholar
  13. Margolin KA, Sondak VK. Melanoma and Other Skin Cancers. In: Pazdur R, Coia L, Hoskins W, Wagman L, editors. Cancer Management: A Multidisciplinary Approach. 8th ed. New York: CMP Healthcare Media; 2004. pp. 509-538.Google Scholar
  14. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Basal Cell and Squamous Skin Cancers. Available at: Accessed on May 7, 2009.
  15. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma. Available at: Accessed on May 7, 2009.
  16. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Melanoma. Available at: Accessed on May 7, 2009.
  17. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol. 1996;34:839-847.Google Scholar
  18. Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697-705.Google Scholar
  19. Solan M, Brady L. Skin Cancer. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and Practice of Radiation Oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. pp. 690-701.Google Scholar
  20. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991; 20(3): 429-432.Google Scholar
  21. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420-2430.Google Scholar
  22. Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956.Google Scholar
  23. Wilder RB, Margolis LW. Cancer of the Skin. In: Leibel SA, Phiilips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 1483-1501.Google Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Tania Kaprealian
    • 1
  • James Rembert
    • 2
  • Lawrence W. Margolis
    • 1
  • Sue S. Yom
    • 1
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Alta Bates Summit Comprehensive Cancer CenterBerkeleyUSA

Personalised recommendations